| Migraine Disorders
Treximet vs Zembrace SymTouch
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Treximet vs Zembrace Symtouch with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZembrace Symtouch has a higher rate of injection site reactions vs Treximet based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zembrace Symtouch but not Treximet, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Treximet
Zembrace Symtouch
At A Glance
Oral
As needed (max 2 doses/24 hrs)
5-HT1 agonist + NSAID
SC injection
As needed
5-HT1B/1D receptor agonist
Indications
- Migraine Disorders
- Migraine Disorders
Dosing
Migraine Disorders - Adults 1 tablet of 85/500 mg orally; max 2 tablets per 24 hours separated by at least 2 hours.
Migraine Disorders - Pediatric Patients 12 to 17 Years 1 tablet of 10/60 mg orally; max 1 tablet of 85/500 mg per 24 hours.
Migraine Disorders - Mild to Moderate Hepatic Impairment 1 tablet of 10/60 mg orally per 24 hours.
Migraine Disorders 3 mg SC injection per dose; max 12 mg per 24 hours with doses separated by at least 1 hour.
Contraindications
- Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina
- Coronary artery bypass graft (CABG) surgery setting
- Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
- History of stroke or transient ischemic attack (TIA), or history of hemiplegic or basilar migraine
- Peripheral vascular disease
- Ischemic bowel disease
- Uncontrolled hypertension
- Recent use (within 24 hours) of ergotamine-containing medication, ergot-type medication (e.g., dihydroergotamine or methysergide), or another 5-HT1 agonist
- Concurrent or recent (within 2 weeks) use of a monoamine oxidase-A (MAO-A) inhibitor
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Known hypersensitivity to sumatriptan, naproxen, or any component of TREXIMET
- Severe hepatic impairment
- Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina
- Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
- History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine
- Peripheral vascular disease
- Ischemic bowel disease
- Uncontrolled hypertension
- Recent (within 24 hours) use of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-HT1 agonist
- Concurrent administration of an MAO-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor
- Known hypersensitivity to sumatriptan (angioedema and anaphylaxis seen)
- Severe hepatic impairment
Adverse Reactions
Most common (>=2%) Dizziness, somnolence, paresthesia, nausea, dyspepsia, dry mouth, chest discomfort/chest pain, neck/throat/jaw pain/tightness/pressure
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, arrhythmias, cerebrovascular events, other vasospasm reactions, hepatotoxicity, hypertension, heart failure and edema, medication overuse headache, serotonin syndrome, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, DRESS, hematological toxicity, exacerbation of aspirin-sensitive asthma, seizures
Postmarketing Exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), fixed drug eruption (FDE)
Most common (>=2%) Injection site reactions, atypical sensations, tingling, dizziness/vertigo, warm/hot sensation, flushing, feeling of heaviness, burning sensation, pressure sensation, weakness, neck pain/stiffness
Serious Myocardial ischemia/infarction, Prinzmetal's angina, arrhythmias, chest/throat/neck/jaw pain or tightness, cerebrovascular events, vasospasm reactions, medication overuse headache, serotonin syndrome, hypertensive crisis, hypersensitivity reactions, seizures
Postmarketing Hypotension, palpitations, dystonia, tremor
Pharmacology
Sumatriptan is a selective 5-HT1B/1D receptor agonist that causes cranial vessel constriction and inhibits trigeminal neuropeptide release to abort migraine; naproxen sodium is an NSAID that inhibits COX-1 and COX-2, reducing prostaglandin synthesis to provide analgesic and anti-inflammatory effects.
Sumatriptan is a selective 5-HT1B/1D receptor agonist that exerts therapeutic effects through agonist activity at receptors on intracranial blood vessels and sensory nerves of the trigeminal system, resulting in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Treximet
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Zembrace Symtouch
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Treximet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Zembrace Symtouch
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Treximet
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Zembrace Symtouch
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Treximet.
No savings programs available for Zembrace Symtouch.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TreximetView full Treximet profile
Zembrace SymtouchView full Zembrace Symtouch profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.